Human deoxyribonuclease I (DNase I), an enzyme recently approved for treatment of cystic fibrosis (CF), has been engineered to create two classes of mutants: actin-resistant variants, which still catalyze DNA hydrolysis but are no longer inhibited by globular actin (G-actin) and active site variants, which no longer catalyze DNA hydrolysis but still bind G-actin. Actin-resistant variants with the least affinity for actin, as measured by an actin binding ELISA and actin inhibition of [33P] DNA hydrolysis, resulted from the introduction of charged, aliphatic, or aromatic residues at Ala-114 or charged residues on the central hydrophobic actin binding interface at Tyr-65 or Val-67. In CF sputum, the actin-resistant variants D53R, Y65A, Y65R, or V67K were 10-to 50-fold more potent than wild type in reducing viscoelasticity as determined in sputum compaction assays. The reduced viscoelasticity correlated with reduced DNA length as measured by pulsed-field gel electrophoresis. In contrast, the active site variants H252A or H134A had no effect on altering either viscoelasticity or DNA length in CF sputum. The data from both the active site and actin-resistant variants demonstrate that the reduction of viscoelasticity by DNase I results
introduction of charged, aliphatic, or aromatic residues at Ala-114 or charged residues on the central hydrophobic actin binding interface at Tyr-65 or Val-67. In CF sputum, the actin-resistant variants D53R, Y65A, Y65R, or V67K were 10-to 50-fold more potent than wild type in reducing viscoelasticity as determined in sputum compaction assays. The reduced viscoelasticity correlated with reduced DNA length as measured by pulsed-field gel electrophoresis. In contrast, the active site variants H252A or H134A had no effect on altering either viscoelasticity or DNA length in CF sputum. The data from both the active site and actin-resistant variants demonstrate that the reduction of viscoelasticity by DNase I results from DNA hydrolysis and not from depolymerization of filamentous actin (F-actin). The increased potency of the actin-resistant variants indicates that G-actin is a significant inhibitor of DNase I in CF sputum. These results further suggest that actin-resistant DNase I variants may have improved efficacy in CF patients. action proposed, wherein DNase I reduces CF sputum viscoelasticity due to the depolymerization of F-actin (7) . Purified actin filaments art known to be depolymerized by DNase I (14, 15) . In addition, F-actin is in equilibrium with its monomeric globular form (G-actin), which interacts with a large number of actin binding proteins including DNase I (16, 17) . G-actin binds DNase I with high affinity and is a potent inhibitor (Ki 1 nM) of DNA hydrolytic activity (18) (19) (20) , potentially influencing the effectiveness of DNase I in vivo. Thus actin in its different forms may have multiple roles with respect to DNase I efficacy in CF sputum.
We sought to elucidate both the basic mechanism of action of human DNase I in CF sputum as well as to assess the significance of G-actin as an inhibitor of DNase I in CF sputum. Our approach was to generate and characterize two classes of mutants: actin-resistant variants that catalyze DNA hydrolysis comparable to wild type but are no longer inhibited by actin, and active site variants which bind actin with affinity comparable to wild type but no longer catalyze DNA hydrolysis. The protein engineering strategy pursued in this paper demonstrates that the reduction of viscoelasticity by DNase I in CF sputum results from DNA hydrolysis and not from depolymerization of F-actin. Furthermore we show that Gactin is a significant inhibitor of DNase I in CF sputum, suggesting that actin-resistant variants may have improved clinical benefit for CF patients.
Respiratory symptoms, recurrent infectious exacerbations, and progressive lung destruction in cystic fibrosis (CF) can be be ascribed to several contributing factors, including a defective CF transmembrane conductance regulator gene, abnormal electrolyte transport, bacterial persistence, and the accumulation of viscous secretions in the airway (1) (2) (3) . In response to these infections leukocytes infiltrate the airways and, upon lysis, release their contents which include DNA and filamentous actin (F-actin)-two macromolecules that contribute to the viscoelastic nature of CF sputum. DNA comprises about 4-10% of the total dry weight of purulent CF sputum (4, 5) ; concentrations up to 20 mg/ml have been observed (D.S., unpublished results). F-actin is an abundant protein in leukocytes (6) ; its concentration in CF sputum is reported to range from 0.1 to 5 mg/ml (7) .
Recombinant human deoxyribonuclease I (DNase I) reduces the viscoelasticity of CF sputum in vitro and improves lung function and reduces respiratory exacerbations in CF patients (8) (9) (10) (11) (12) . The ability of DNase I to reduce the viscoelasticity of pulmonary secretions has been attributed to the enzymatic hydrolysis of DNA (8, 13 §To whom reprint requests should be addressed.
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were compared with standard curves of purified recombinant human DNase I (Pulmozyme; Genentech) to determine concentrations. The relative specific activity is defined as the DNase I concentration determined in the methyl green assay divided by the DNase I concentration determined in the DNase I ELISA; the data are normalized to wild-type DNase I. Actin Binding ELISA. MaxiSorp plates (Nunc) were coated with 100 ,ul human Gc globulin (Calbiochem) at 10 ,ug/ml in 25 mM Hepes (pH 7.2), 4 mM MgCl2, and 4 mM CaCl2 at 4°C for 16-24 h. After discarding the Gc globulin, excess reactive sites were blocked with 200 ,ul buffer A (25 mM Hepes, pH 7.5/4 mM CaCl2/4 mM MgCl2/0.1% BSA/0.5 mM ATP/ 0.01% thimerosal/0.05% Tween 20) . Buffer A was used in all dilution steps unless otherwise noted; incubations were at room temperature for 1 h. The wash buffer was PBS containing 0.05% Tween 20. Rabbit skeletal muscle G-actin [1 mg/ml; prepared by the method of Pardee and Spudich (25) or obtained from Sigma] was dialyzed overnight at 4°C against 5 mM Hepes (pH 7.2), 0.2 mM CaCl2, 0.5 mM ATP, and 0.5 mM 2-mercaptoethanol. After centrifugation at 13,000 x g for 5 min, the amount of G-actin-ATP was quantitated by measuring the absorbance at 290 nm, using 290 = 28.3 mM-1'cm-1 (19) .
Following the addition of 100 gl of 50 ,ug of G-actin per ml in buffer A, the plates were incubated and washed, and 100 ,lI of cell culture harvest at various dilutions was added. After incubation and washing, 100 pul of anti-human DNase I rabbit polyclonal antibody-horseradish peroxidase conjugate (19 ng/ ml) was added. Following incubation and washing, color development was initiated by adding 100 plI per well of Sigma Fast o-phenylenediamine and urea/H202 reagent (prepared according to Sigma) and stopped by adding 100 ,ul per well 4.5 M H2SO4. The A492 was measured and plotted versus the DNase I concentration. The resultant sigmoidal curves were fit to a four parameter equation by nonlinear regression analysis (26) ; the EC5o value is the DNase I concentration that produced a half-maximal signal.
Actin Inhibition Assays. Varying concentrations of G-actin were preincubated in duplicate for 15 min at room temperature with 0.54 nM DNase I variant in buffer A containing 0.5 mM 2-mercaptoethanol and 150 mM NaCl. Reactions were initiated by the addition of 33P-labeled M13 DNA and salmon testes DNA (Sigma) to a final concentration of 4.1 ,ug/ml, incubated at room temperature for 2 h, and quenched with 25 mM EDTA and cold TCA (6.7% final concentration). After 10 min on ice samples were centrifuged at 9300 x g for 5 min at 4°C and the acid-soluble counts determined. Plots of the fractional activity (cpm inhibited/cpm uninhibited) versus actin concentration were fit by nonlinear regression analysis using KALEIDAGRAPH version 3.0. CF Sputum Compaction Assays. Assays using CF sputum collected from four patients and stored at -80°C prior to use were carried out as described (27) ; sputa were incubated in triplicate with DNase I samples at various concentrations for 20 min at room temperature.
Pulsed-Field Gel Electrophoresis. Pulsed-field gel electrophoresis was carried out in 1% agarose gels; after electrophoresis, gels were stained with ethidium bromide and imaged in a Molecular Dynamics Fluorimager.
RESULTS AND DISCUSSION
Protein Engineering. Selected mutations were made based on the x-ray crystal structures of bovine DNase I complexed with either G-actin or DNA (28, 29) . A model of a ternary complex of DNase I, actin, and DNA, constructed by superimposing the DNase I structures (28) (29) (30) , shows that the DNA and actin binding sites are adjacent yet distinct; the inhibition of DNase I by actin due to steric hindrance is apparent (Fig.  1) . Bovine pancreatic DNase I shares 78% identity and superimposes with an overall rms deviation for main chain atoms of 0.56 A with the human enzyme, recently solved at 2.2-A resolution (30) . The contact residues at the actin binding interface as well as those at active site are conserved. Both human and bovine DNase I have been found to reduce the viscosity of purulent sputum (8, 13) .
The binding of DNase I to actin involves hydrophobic, electrostatic, and hydrogen bonding interactions over a buried surface area of 1849 A2 (17, 28) ; the actin binding interface is shown in Fig. 2 'v' with wild type, demonstrating that changes at the actin binding interface do not affect the active site ( Fig. 3 A and C) .
The binding affinity of DNase I variants for G-actin was assessed by an ELISA where actin was bound to immobilized Gc globulin, a protein whose affinity for actin is unaffected by DNase I (33-35) ; the EC5o values are plotted in Fig. 3 (Fig. 3D) (Fig. 3D) . This large effect is likely due to steric hindrance, since Ala-114 resides on an internal 3-strand and lies at the bottom of a pocket with its side chain in van der Waals contact with that of Val-45 of actin (Fig. 2) . The introduction of charge on the central hydrophobic interface at Tyr-65 and Val-67 (Y65R, V67K, V67D) also greatly impaired actin binding (Figs. 2 and 3D ). The fact that Y65R and V67K are much more actin resistant than Y65W or V67M implicates charge rather than steric hindrance as the critical factor. Moderate reductions in actin binding were noted upon removal of the aromatic side-chain at Tyr-65 (Y65A) and introduction of a charge reversal at Asp-53 (D53R), which should disrupt the salt bridge formed with Arg-39 and the hydrogen bonds to His-40 of actin ( Fig. 3D and Table 1 ). >10,000
The inhibition constants (Ki) were calculated using the known concentrations of DNase I variant and G-actin, the measured fractional activity, and fitting the data by nonlinear regression analysis to the equation for tight binding reversible inhibition as described in Materials and Methods.
actin, had minimal effects ( Fig. 3D and Table 1 ), suggesting that their contributions to the binding energy of the complex are negligible.
Activity of DNase I Variants in CF Sputum. Sputum compaction assays were used to measure the relative viscoelasticity of CF sputum after incubation with wild-type and selected DNase I variants (27) ; the percent change in compaction is shown in Fig. 4 . The active site variants (H134A, H252A), which no longer catalyze DNA hydrolysis but still bind G-actin and could therefore depolymerize F-actin, did not reduce sputum viscoelasticity. However, both wild type and the actinresistant variants tested (D53R, Y65A, Y65R, V67K) decreased viscoelasticity in a dose-dependent manner. The data from both sets of mutants demonstrate that the reduction in sputum viscoelasticity by DNase I results from DNA hydrolysis and not actin depolymerization. The hydrolysis of DNA in CF sputum and subsequent reduction in DNA length by wild type and the actin-resistant variant V67K was confirmed using pulsed-field gel electrophoresis (Fig. 5) ; no reduction in DNA length was seen with the active site variant H134A (D.S., unpublished results).
Most importantly, the actin-resistant variants were about 10 to 50-fold more potent in both reducing sputum viscoelasticity and in reducing DNA length compared with wild-type DNase I (Fig. 4 and 5) . Based on these results, we conclude that G-actin is a significant inhibitor of DNase I in CF sputum, and that the actin-resistant variants are not subject to this inhibi- 4. Biological Significance and Clinical Implications. The biological significance of DNase I inhibition by actin is not well understood; a potential role during mitosis and apoptosis has been recently proposed (36) . DNase I from mammalian sources is highly conserved (37); however, not all mammalian DNases are inhibited by actin (38, 39) 
